Characterizing genetic and protein changes in adult AML patients with specific rearrangements

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This academic, multicenter study focuses on patients with acute myeloid leukemia (AML) who have MECOM or atypical 3q26 rearrangements. It aims to collect and analyze bone marrow samples and biopsies to characterize the genome, transcriptome, and proteome of these patients. The study will gather data before and after treatment, as well as at relapse, to better understand the biological underpinnings of this specific AML subtype.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* AML with MECOM or atypical 3q26 rearrangements.
* Age ≥18.
* Signed written informed consent according to ICH/EU/GCP and national local laws.

Exclusion Criteria:

* None

Where it's running

• Ematologia
  Piacenza, Italy Recruiting

Study contacts

• Principal investigator: Giovanni Roti — Department of Medicine and Surgery, University of Parma, Parma
• Study coordinator: Paola Fazi
• Email: p.fazi@gimema.it
• Phone: 0670390528

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Quality-of-life–guided red blood cell transfusions for people with refractory MDS or AML

  We test whether using routine EQ-5D-5L quality-of-life scores to decide when to give red blood cell transfusions can safely reduce the number of transfusions for adults with refractory MDS or AML who are receiving only palliative care.

  Recruiting Centre Hospitalier Universitaire de Nice · Nice · NCT07328191

• Venetoclax plus Azacitidine versus Daunorubicin/Idarubicin plus Cytarabine induction for fit older adults with AML

  This trial will test whether Venetoclax plus Azacitidine works as well as standard daunorubicin or idarubicin plus cytarabine induction in fit adults aged 55–75 with acute myeloid leukemia.

  Recruiting Phase 3 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT07132684

• Post-remission treatments for MRD-positive adult AML

  This study will try different drug regimens to see if they help people aged 14 and older with AML who are in remission but still MRD-positive stay relapse-free and live longer.

  Recruiting Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07131059

• Venetoclax plus a short (3-day) decitabine schedule for untreated elderly or unfit adults with AML

  This trial will see if venetoclax combined with a short (3-day) decitabine course helps people with newly diagnosed AML who are elderly or cannot receive standard chemotherapy.

  Recruiting The Second Hospital of Hebei Medical University · Hebei · NCT07117422

• Observational study of older patients with acute myeloid leukemia receiving intensive treatment

  This study looks at older patients with acute myeloid leukemia to see how well intensive treatment works for them and what factors might affect their recovery and survival.

  Recruiting at 27 sites French Innovative Leukemia Organisation · Angers and 26 other locations · NCT06891144

• Using eganelisib alone and with cytarabine for treating relapsed/refractory AML

  This study is testing if a new drug called eganelisib, used alone or with another drug called cytarabine, can help people with relapsed or hard-to-treat acute myeloid leukemia feel better.

  Recruiting at 12 sites Phase 1 Stelexis BioSciences · Duarte, California and 11 other locations · NCT06533761

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.